Abstract: . . .  Warfarin Ximelagatran Page 30 Conclusions Conclusions Fixed oral dosing without coagulation monitoring Fixed oral dosing without coagulation monitoring Effectiveness non Effectiveness non - - inferior to well inferior to well - - controlled controlled warfarin warfarin in in preventing stroke and systemic embolic events preventing stroke and systemic embolic events Less bleeding than Less bleeding than warfarin warfarin Elevated liver enzymes in 6% of patients Elevated liver enzymes in 6% of patients A promising treatment option for prevention of A promising treatment option for prevention of thromboembolism thromboembolism In high In high - - risk patients with risk patients . . .
. . .  well - - controlled controlled warfarin warfarin in in preventing stroke and systemic embolic events preventing stroke and systemic embolic events Less bleeding than Less bleeding than warfarin warfarin Elevated liver enzymes in 6% of patients Elevated liver enzymes in 6% of patients A promising treatment option for prevention of A promising treatment option for prevention of thromboembolism thromboembolism In high In high - - risk patients with risk patients with atrial atrial fibrillation , fibrillation , ximelagatran ximelagatran offers: offers:  . . .
. . .  events Less bleeding than Less bleeding than warfarin warfarin Elevated liver enzymes in 6% of patients Elevated liver enzymes in 6% of patients A promising treatment option for prevention of A promising treatment option for prevention of thromboembolism thromboembolism In high In high - - risk patients with risk patients with atrial atrial fibrillation , fibrillation , ximelagatran ximelagatran offers: offers:  . . .
--3000,3,500,2684,29726